Lung Cancer
Conference Coverage
Circulating tumor cells predict NSCLC survival, but clinical role uncertain
GENEVA - CTC counts of at least 5 cells per 7.5 mL were associated with reduced overall survival in a retrospective analysis involving 550...
Conference Coverage
PACIFIC: Patient-reported outcomes unaffected by PD-L1 expression
GENEVA – Level of programmed death-ligand 1 expression does not impact patient-reported outcomes among those...
Conference Coverage
Osimertinib again shows strength in NSCLC with leptomeningeal metastases
GENEVA – The overall response rate was 55% for patients with NSCLC and leptomeningeal metastases receiving...
Video
Dr. Douglas Paauw gives updates on antihypertensives, statins, SGLT2 inhibitors
PHILADELPHIA – This past year has been a tough one for ARBs.
From the Journals
First-line afatinib responses encouraging across diverse population of EGFR TKI-naive patients
GENEVA – The objective response rate was 46% in an interim analysis of EGFR TKI-naive patients with locally advanced...
Conference Coverage
Liquid biopsy falls short for isolated brain lesions in lung cancer
GENEVA – Plasma circulating tumor DNA analysis detected molecular abnormalities in almost all patients with systemic...
Conference Coverage
Novel CAR T, anti-PD-1 combo shows promise in MPD
ATLANTA – Intrapleurally administered, mesothelin-targeted CAR T-cell therapy combined with PD-1 inhibition showed antitumor activity without...
Conference Coverage
Adding MET TKI may overcome NSCLC resistance
ATLANTA – Combining the investigational MET inhibitor savolitinib to osimertinib was associated with responses in NSCLC resistant to EGFR-targeted...
From the Journals
Data from routine lung cancer visits yield research insights
A clinicogenomic database identified associations between clinical and genetic characteristics and treatment responses.
Conference Coverage
Afatinib shows safety and efficacy among elderly
GENEVA – In a retrospective analysis of the GIDEON phase 3 trial involving patients with EGFR-positive NSCLC, there...
Conference Coverage
Larotrectinib responses support routine NTRK gene fusion testing for lung cancer
GENEVA – Although NTRK fusions are relatively infrequent in lung cancer, a subgroup analysis demonstrates an overall...